The venture's focus on AI/biotech and drug discovery aligns with the French government's priorities for grant funding, including health and research commercialization. The founder's proof-of-concept validation and strong technical background also increase the likelihood of a successful grant application. With the venture's pre-seed stage and plans to operate in France, this grant is a strong fit.